Who is eligible for clinical trial NCT02994719?

Participants must meet the protocol's inclusion criteria for Parkinson's Disease. The stated age range is 18 Years to 85 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT02994719 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-06

Gait Analysis in Neurological Disease (NCT02994719)

Gait Pattern Analysis in Neurological Disease

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Beth Israel Deaconess Medical Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).

Location: Clinical Research Center BIDMC — Boston, Massachusetts

Age range: 18 Years to 85 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age 18-85 (for both healthy and affected subjects).
Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).
Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).
These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).
Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).
Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).
Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects).
Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).
Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).
Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \< 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Clinical Research Center BIDMC — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Parkinson's Disease

Genotypic Influences on Network Progression in Parkinson's Disease — Manhasset, New York
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics — Boston, Massachusetts
Non-invasive VNS for Parkinson's Gait — Hines, Illinois
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Phoenix, Arizona
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease — New Haven, Connecticut
Modifiable Variables in Parkinsonism (MVP) — Kenmore, Washington

Explore by condition: All Parkinson's Disease clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗